<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04990349</url>
  </required_header>
  <id_info>
    <org_study_id>ECMOxy - pilot study</org_study_id>
    <nct_id>NCT04990349</nct_id>
  </id_info>
  <brief_title>Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation in Patients Supported by Veino-arterial ECMO for Cardiogenic Shock</brief_title>
  <acronym>ECMOxy</acronym>
  <official_title>Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation : Impact on Organ Dysfunction in Patients Supported by Veino-arterial ECMO for Cardiogenic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Because of dual oxygenation and oxygenator performance (PO2 postoxygenator up to 500 mmHg),&#xD;
      hyperoxemia (PaO2 &gt; 150 mmHg) is frequent in veino-arterial ECMO, especially in the lower&#xD;
      part of the body, which is mainly oxygenated by ECMO.&#xD;
&#xD;
      By enhancing oxygen free radicals' production, hyperoxemia might favor gut, kidney and liver&#xD;
      dysfunction.&#xD;
&#xD;
      We hypothesize that targeting an extracorporeal normoxemia (i.e. PO2 postoxygenator between&#xD;
      100 and 150 mmHg) will decrease gut, kidney and liver dysfunctions, compared to a liberal&#xD;
      extracorporeal oxygenation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomization:&#xD;
&#xD;
      Patients will be randomized in the 6 hours following ECMO start in the normoxemia or in the&#xD;
      hyperoxemia group. Randomization will be stratified on center, and medical or postcardiotomy&#xD;
      indication for ECMO.&#xD;
&#xD;
      Description of experimental arm (Normoxemia group):&#xD;
&#xD;
        -  After randomization, extracorporeal normoxemia is targeted by setting the ECMO membrane&#xD;
           oxygen fraction (FmO2) at 60%.&#xD;
&#xD;
        -  The objective is to maintain oxygen partial pressure measured on the arterial cannula&#xD;
           (PO2 postoxygenator) between 100 and 150 mmHg.&#xD;
&#xD;
        -  PO2 postoxygenator is monitored at least twice a day by the nurse.&#xD;
&#xD;
        -  If PO2 postoxygenator is less than 100 mmHg or more than 150 mmHg, FmO2 is modified by&#xD;
           10% and PO2 postoxygenator is monitored 10 minutes after.&#xD;
&#xD;
        -  Ventilator's settings at let to the clinician's discretion. However, PaO2 on right&#xD;
           radial artery will be monitored to ensure that is more that 80 mmHg.&#xD;
&#xD;
        -  Intervention will be applied for 7 days after randomization.&#xD;
&#xD;
      Description of the control arm (Hyperoxemia group):&#xD;
&#xD;
        -  After randomization, extracorporeal hyperoxemia is targeted by setting the ECMO membrane&#xD;
           oxygen fraction (FmO2) at 100%.&#xD;
&#xD;
        -  The objective is to maintain PO2 postoxygenator higher than 300 mmHg.&#xD;
&#xD;
        -  PO2 postoxygenator is monitored at least twice a day by the nurse.&#xD;
&#xD;
        -  If PO2 postoxygenator is less than 300 mmHg, membrane change should be discussed.&#xD;
&#xD;
        -  Ventilator's setting at let to the clinician's discretion. However, PaO2 on right radial&#xD;
           artery will be monitored to ensure that is more that 80 mmHg.&#xD;
&#xD;
        -  Intervention will be applied for 7 days after randomization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial with two arms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Enterocyte damage</measure>
    <time_frame>At day 2</time_frame>
    <description>Plasma Intestinal Fatty Acid Biding Protein (I-FABP) concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of the oxygenation protocol</measure>
    <time_frame>From day 0 to day 6</time_frame>
    <description>Percentage of time in the oxygenation target</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Security of the oxygenation protocol</measure>
    <time_frame>From day 0 to day 6</time_frame>
    <description>Number of right radial PaO2 below 80 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ failure</measure>
    <time_frame>From day 0 to day 30</time_frame>
    <description>Death or severe stroke (NIHSS &gt; 11) or mesenteric ischemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ failure</measure>
    <time_frame>At day 0, day 2 and day 6</time_frame>
    <description>Non cardiac component of the Sequential Organ Failure Assessment (SOFA) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ failure</measure>
    <time_frame>At day 0, day 2 and day 6</time_frame>
    <description>Plasma lactate concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enterocyte damage</measure>
    <time_frame>At day 0, and day 1</time_frame>
    <description>Plasma Intestinal Fatty Acid Biding Protein (I-FABP) concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enterocyte function</measure>
    <time_frame>At day 0 and day 2</time_frame>
    <description>Difference between plasma citrulline concentrations at day 0 and day 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver failure</measure>
    <time_frame>At day 0, day 2 and day 6</time_frame>
    <description>Plasma Aspartate aminotransferase (ASAT) concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver failure</measure>
    <time_frame>At day 0, day 2 and day 6</time_frame>
    <description>Prothrombine time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal failure</measure>
    <time_frame>At day 0, day 2 and day 6</time_frame>
    <description>Plasma creatinine concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal failure</measure>
    <time_frame>From 0 to day 6</time_frame>
    <description>Need for renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic inflammation</measure>
    <time_frame>At day 0, day 2 and day 6</time_frame>
    <description>Plasma CRP, TNF alpha, IL6 and IL8 concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-oxydant stock</measure>
    <time_frame>At day 0, day 2 and day 6</time_frame>
    <description>Plasma vitamin C, vitamin E, and Glutathion concentrations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cardiogenic Shock</condition>
  <condition>Extracorporeal Membrane Oxygenation</condition>
  <arm_group>
    <arm_group_label>Extracorporeal normoxemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After randomization, extracorporeal normoxemia is targeted by setting the ECMO membrane oxygen fraction (FmO2) at 60%.&#xD;
The objective is to maintain oxygen partial pressure measured on the arterial cannula (PO2 postoxygenator) between 100 and 150 mmHg.&#xD;
PO2 postoxygenator is monitored at least twice a day by the nurse.&#xD;
If PO2 postoxygenator is less than 100 mmHg or more than 150 mmHg, FmO2 is modified by 10% and PO2 postoxygenator is monitored 10 minutes after.&#xD;
Ventilator's setting at let to the clinician's discretion. However, PaO2 on right radial artery will be monitored to ensure that is more that 80 mmHg.&#xD;
Intervention will be applied for 7 days after randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extracorporeal hyperoxemia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After randomization, extracorporeal hyperoxemia is targeted by setting the ECMO membrane oxygen fraction (FmO2) at 100%.&#xD;
The objective is to maintain PO2 postoxygenator higher than 300 mmHg.&#xD;
PO2 postoxygenator is monitored at least twice a day by the nurse.&#xD;
If PO2 postoxygenator is less than 300 mmHg, membrane change should be discussed.&#xD;
Ventilator's setting at let to the clinician's discretion. However, PaO2 on right radial artery will be monitored to ensure that is more that 80 mmHg.&#xD;
Intervention will be applied for 7 days after randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen gas</intervention_name>
    <description>Targeted PO2 postoxygenator is obtained by modulating ECMO Membrane oxygen fraction.</description>
    <arm_group_label>Extracorporeal hyperoxemia</arm_group_label>
    <arm_group_label>Extracorporeal normoxemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient supported by veino-arterial ECMO for cardiogenic shock for less than 6 hours&#xD;
&#xD;
          -  Affiliation to social protection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 ans&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Opposition of the patient or his relatives&#xD;
&#xD;
          -  Cannulation during cardiopulmonary resuscitation&#xD;
&#xD;
          -  Cardiopulmonary resuscitation duration &gt; 10 minutes before ECMO implantation&#xD;
&#xD;
          -  Patient moribound on the day of randomization&#xD;
&#xD;
          -  Chronic hemodialysis&#xD;
&#xD;
          -  Chronic intestinal disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hadrien Winiszewski, MD</last_name>
    <phone>03 81 66 81 27</phone>
    <email>hwiniszewski@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gilles Capellier, MD, PhD</last_name>
    <phone>03 81 66 81 27</phone>
    <email>gilles.capellier@univ-fcomte.fr</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Munshi L, Kiss A, Cypel M, Keshavjee S, Ferguson ND, Fan E. Oxygen Thresholds and Mortality During Extracorporeal Life Support in Adult Patients. Crit Care Med. 2017 Dec;45(12):1997-2005. doi: 10.1097/CCM.0000000000002643.</citation>
    <PMID>28787294</PMID>
  </results_reference>
  <results_reference>
    <citation>Hayes RA, Shekar K, Fraser JF. Is hyperoxaemia helping or hurting patients during extracorporeal membrane oxygenation? Review of a complex problem. Perfusion. 2013 May;28(3):184-93. doi: 10.1177/0267659112473172. Epub 2013 Jan 15. Review.</citation>
    <PMID>23322670</PMID>
  </results_reference>
  <results_reference>
    <citation>Chou HC, Chen CM. Neonatal hyperoxia disrupts the intestinal barrier and impairs intestinal function in rats. Exp Mol Pathol. 2017 Jun;102(3):415-421. doi: 10.1016/j.yexmp.2017.05.006. Epub 2017 May 12.</citation>
    <PMID>28506763</PMID>
  </results_reference>
  <results_reference>
    <citation>Falk L, Sallisalmi M, Lindholm JA, Lindfors M, Frenckner B, Broomé M, Broman LM. Differential hypoxemia during venoarterial extracorporeal membrane oxygenation. Perfusion. 2019 Apr;34(1_suppl):22-29. doi: 10.1177/0267659119830513.</citation>
    <PMID>30966908</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>July 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiogenic shock</keyword>
  <keyword>Extracorporeal Membrane Oxygenation</keyword>
  <keyword>Hyperoxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>2023</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

